KRAS and cancer: In particular, it has been reported that RTK–SOS2–WT RAS signaling, but not allosteric SOS2 activation, is a critical mediator of mutant KRAS-driven transformation [31] by protecting KRAS-mutated cancer cells from anoikis [32].